Abiopharma

🔍 Khattar Jack A. (Director)

Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Acquired 73,176 shares of Common Stock at $25.3 per share (Direct)
  Date: 2025-09-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,165,809.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 55,578 shares of Common Stock at $46.01 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,110,231.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-05 | Code: H | nature_of_ownership: By the KBT Trust | shares_owned_after: 1,005,600.00
• Sold 73,176 shares of Employee Stock Option (Right to Buy) at $25.3 per share (Derivative)
  Date: 2025-09-05 | Code: M | Expires: 2027-02-24 | Exercise: 2018-02-24 | equity_swap_involved: 0 | shares_owned_after: 170,574.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.09. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
• F3: The option vests in four equal installments beginning on February 24, 2018.